https://mindmedicinelaw.com/briefing/psychedelic-healing-initiative-for-system-impacted-individuals-20260618-14320The Psychedelic Journalen2026-06-18T22:04:06.073895+00:00Psychedelic Healing Initiative for System-Impacted Individualspsychedelic-assisted healing, system-impacted individuals, marginalized communities, policy reform, public health, clinical trials, psilocybin, MDMA, equity in research, therapeutic potentialhttps://mindmedicinelaw.com/briefing/durable-change-framework-in-psychiatry-implications-for-trials-20260617-14083The Psychedelic Journalen2026-06-18T15:04:51.772159+00:00Durable Change Framework in Psychiatry: Implications for Trialspsychiatric treatment, high-plasticity brain states, clinical trial design, psychedelic-assisted therapy, brain plasticity, durable psychological change, critical periods, transcranial magnetic stimulation, deep brain stimulation, treatment efficacyhttps://mindmedicinelaw.com/briefing/community-driven-psilocybin-therapy-study-in-new-mexico-20260617-14046The Psychedelic Journalen2026-06-18T15:04:39.160785+00:00Community-Driven Psilocybin Therapy Study in New Mexicopsilocybin therapy, community engagement, PTSD treatment, New Mexico, equitable access, economic analysis, clinical trials, psychedelic research, mental health, policy implicationshttps://mindmedicinelaw.com/briefing/psilocybin-s-long-term-antidepressant-effects-clinical-insights-20260617-13999The Psychedelic Journalen2026-06-17T22:04:00.156832+00:00Psilocybin's Long-Term Antidepressant Effects: Clinical Insightspsilocybin, antidepressant effects, psychotherapy, depression treatment, psychedelic therapy, clinical guidelines, mental health, FDA, serotonin receptors, psychedelic researchhttps://mindmedicinelaw.com/briefing/youth-addiction-interventions-insights-and-challenges-20260616-14066The Psychedelic Journalen2026-06-18T15:05:01.743051+00:00Youth Addiction Interventions: Insights and Challengesyouth addiction interventions, substance addiction, behavioral addiction, children and adolescents, psychotherapy, educational interventions, public health, addiction research, early intervention, stakeholder collaborationhttps://mindmedicinelaw.com/briefing/oregon-court-case-examines-psilocybin-home-access-laws-20260616-13522The Psychedelic Journalen2026-06-17T22:04:09.198285+00:00Oregon Court Case Examines Psilocybin Home Access Lawspsilocybin, Oregon law, home access, psychedelic regulation, Measure 109, legal precedent, community practices, state policy, court case, public safetyhttps://mindmedicinelaw.com/briefing/kmt-as-adjunct-to-cbt-for-bipolar-disorder-potential-and-challenges-20260615-13774The Psychedelic Journalen2026-06-17T22:04:34.123976+00:00KMT as Adjunct to CBT for Bipolar Disorder: Potential and Challengesketogenic metabolic therapy, cognitive behavioral therapy, bipolar disorder, mental health treatment, therapy participation, mood stability, clinical trials, psychotherapy, treatment adherencehttps://mindmedicinelaw.com/briefing/comt-gene-polymorphism-and-ocd-risk-in-bangladesh-20260615-13730The Psychedelic Journalen2026-06-17T22:04:25.662070+00:00COMT Gene Polymorphism and OCD Risk in BangladeshCOMT gene, OCD risk, Bangladesh, genetic polymorphism, Val158Met, dopamine metabolism, psychiatric disorders, case-control study, genotyping, personalized treatmenthttps://mindmedicinelaw.com/briefing/orexins-influence-epileptiform-activity-in-rat-hippocampus-20260615-13775The Psychedelic Journalen2026-06-17T22:04:17.086967+00:00Orexins Influence Epileptiform Activity in Rat Hippocampusorexins, epileptiform activity, hippocampus, orexin-A, OX1 receptor, epilepsy treatment, neuroscience, clinical trials, rat models, neuropeptideshttps://mindmedicinelaw.com/briefing/scoping-review-on-modern-mental-health-challenges-20260613-13731The Psychedelic Journalen2026-06-17T22:04:40.547101+00:00Scoping Review on Modern Mental Health Challengesmental health challenges, integrated interventions, culturally responsive, digital mental health, climate anxiety, equity in mental health